Jaguar Animal Health, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. This is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide a clear Q4-only financial breakdown. The company was an early-stage animal-health business developing gastrointestinal products and had not generated material operating revenue.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Revenue | $141,523 | $258,381 |
| Cost of revenue | $51,966 | $123,457 |
| Gross profit and margin | $89,557; 63.3% | $134,924; 52.2% |
| Research and development expense | $7.21 million | $6.48 million |
| Sales and marketing expense | $485,440 | $765,091 |
| General and administrative expense | $5.98 million | $5.34 million |
| Operating loss | $13.59 million | $12.45 million |
| Net loss | $14.73 million | $16.29 million |
| Cash used in operating activities | $14.41 million | $14.32 million |
- Revenue fell 45.2%, principally due to lower Neonorm Calf unit sales. It included $24,000 from botanical-extract sales to a China distributor.
- R&D rose 11.3%, reflecting higher personnel and consulting/formulation costs; sales and marketing declined 36.6%. G&A increased 12.1%.
- Net loss narrowed year over year, largely alongside lower interest expense and warrant remeasurement expense; operating loss increased as operating expenses rose.
- Cash and cash equivalents were $951,000 at year-end, down from $7.70 million. Restricted cash was $511,000. Current assets were $2.56 million versus current liabilities of $4.19 million; stockholders’ deficit was $2.45 million.
- Net long-term debt was $3.74 million, including $1.92 million current and $1.82 million long-term; a separate $150,000 convertible note remained outstanding. Scheduled 2017 principal payments were approximately $2.03 million, with a $560,000 end-of-term payment due in 2018.
- Financing provided $5.28 million in 2016, including follow-on equity proceeds and share sales; investing activities provided $2.38 million, primarily from release of restricted cash. Year-end liquidity was not sufficient to fund the business plan.
Business developments and outlook
- Canalevia, a crofelemer prescription candidate for canine diarrhea, completed enrollment of 200 dogs in its pivotal acute-diarrhea field study in January 2017. Top-line results were expected in the first half of 2017, with major NADA sections targeted for mid-2017. The company anticipated a 2017 conditional-approval launch for chemotherapy-induced diarrhea, if approved, and an early-2018 launch for acute diarrhea, if approved.
- Equilevia is being developed for equine gastric ulcers. A 121-horse dose-determination study completed enrollment in November 2016; the filing said full analysis was expected in Q1 2017 and a pivotal field study was planned. Exploratory racing-performance observations were not statistically significant.
- Neonorm Calf and Neonorm Foal were commercial products, but revenue remained limited. The company reported favorable user feedback and positive study results for a second-generation calf formulation; these products’ regulatory status and commercial traction remain important uncertainties.
- Elanco agreement (January 2017): Jaguar received a $1.5 million upfront payment and could receive up to $61 million in development, regulatory and sales milestones, plus expense reimbursement and sales royalties. Elanco received exclusive global rights outside the U.S. and co-exclusive U.S. rights for covered products; Jaguar retained commercial responsibility for the canine chemotherapy-induced-diarrhea indication. Jaguar is responsible for supplying products.
- Proposed Napo merger (February 2017): The binding terms contemplated a 3-to-1 Napo-to-Jaguar value ratio, required approvals and other closing conditions, and a third-party $3 million investment in Jaguar, with proceeds loaned to Napo. If the merger failed to close under specified circumstances by July 31, 2017, Jaguar could be required to issue Napo 2 million restricted shares. The filing described significant potential dilution and transaction risks.
- Management expected increased 2017 spending and continued losses. The auditor’s report and management disclosed substantial doubt about Jaguar’s ability to continue as a going concern; available cash was not expected to fund operations for the next 12 months. Additional financing or cost reductions would be needed, with no assurance of funding on acceptable terms.
Key risks and unusual items
- Jaguar depended on regulatory approvals, trial outcomes, third-party manufacturers and distributors, and continued financing; no prescription candidate had FDA approval.
- NASDAQ had notified the company of noncompliance with the minimum stockholders’ equity requirement and the $1.00 minimum bid-price requirement. The filing described deadlines to regain compliance and delisting risk.
- The 2016 private placement generated approximately $1 million gross and included substantial warrants; total warrants outstanding reached 5.97 million at year-end. Equity financing and potential exercises could materially dilute shareholders.
- A $108,000 loss on extinguishment of debt arose from extending a $150,000 convertible note and issuing a warrant. The note’s maturity was subsequently extended to January 1, 2018.
- Patent protection relied substantially on Napo-licensed intellectual property; key underlying patents were approaching expiration, and Jaguar disclosed no issued patents of its own at year-end.
- The filing reported no pending legal proceedings expected to have a material adverse effect and no material changes in internal control over financial reporting during Q4 2016.
Important facts for investors to verify
- Current cash runway, financing obtained after filing, and the ability to meet debt payments and fund development.
- Canalevia pivotal-study results, FDA review and approval timing, and actual terms and payments under the Elanco agreement.
- Equilevia dose-study analysis and progress toward a pivotal trial; distinguish exploratory findings from statistically significant evidence.
- Status and final economics of the proposed Napo merger, including approvals, debt limits, dilution, the potential 2-million-share payment, and NASDAQ listing implications.
- Neonorm sell-through, distributor minimum-purchase commitments, and regulatory status in the U.S. and international markets.
- NASDAQ compliance status and the fully diluted share count, including warrants, options and financing-related securities.